# About Wolverine Buy: An Editorial Record of BPC-157 TB-500 Research

> Wolverine Buy is an independent editorial project that publishes summaries of the peer-reviewed research on the BPC-157 TB-500 blend. Not a clinic, not a vendor, not a prescription.

An independent editorial project that reads the published literature on the Wolverine blend and carves it into a sourced, plain record.

## What this site is

Wolverine Buy is an independent editorial project that publishes summaries of the peer-reviewed research literature on the **BPC-157 TB-500** blend and its two constituents. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site is built as a carved field record: each finding is logged to its source, each peptide is marked to the studies it actually derives from, and the gaps in the record — chief among them the absence of any controlled combination trial — are kept visible rather than smoothed over. Where a claim is quantitative, it cites a study you can open and read.

## On the name

The "Buy" in the domain name is editorial framing, not a service. This site sells nothing and supplies nothing. We read "buy" as the act of acquiring the record — gathering and provenancing the literature — rather than acquiring a substance. There is no checkout here, no pricing, no vendor relationship, and no path to obtaining either peptide.

"Wolverine" is the research-community nickname for the BPC-157 + TB-500 pairing. We use it because that is what the literature and the forums call the blend, not because the site is affiliated with any product, brand, or character of that name. The compound terms we actually index are BPC-157 and TB-500.

## How we read the evidence

Our standard is the published record. We summarize what studies measured, in which species, at which dose, by which route — and we attribute every figure. We do not translate animal-model parameters into human guidance, and we do not present the community's fixed-ratio vials or loading protocols as validated dosing, because no controlled trial supports them.

We also keep the regulatory record current and sourced, including the FDA 503A status of both constituents and their appearance on the July 2026 Pharmacy Compounding Advisory Committee agenda. We report present-tense regulatory facts and cite FDA directly; we do not assert any future FDA decision as a certainty. The aim is a record a reader can trust precisely because it shows its sources and marks its limits.

---

Two complementary repair signals carved as two mirrored glyph-channels — BPC-157 read against its studies on one side, TB-500 against its own on the other, the join between them left uncarved because no combination trial exists, and the FDA 503A and WADA record set in the margin; no clinic behind the tablet and nothing here dispensed.